CoChat
Sign Up
Cited by 785Pain Mechanisms and TreatmentsPain Management and TreatmentPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Treatment of neuropathic pain: an overview of recent guidelines.

O'Connor, Alec B., Dworkin, Robert H.·2009·The American Journal of Medicine
DOI 10.1016/j.amjmed.2009.04.007
Open this paper in CoChat — free account

Abstract

A number of different treatments for neuropathic pain have been studied, but the literature is sizable, rapidly evolving, and lacks important information about practical aspects of patient management. Under the auspices of the International Association for the Study of Pain (IASP) Neuropathic Pain Special Interest Group (NeuPSIG), a consensus process was used to develop evidence-based guidelines for the pharmacologic management of neuropathic pain that take into account clinical efficacy, adverse effects, impact on health-related quality of life, convenience, and costs. On the basis of randomized clinical trials, medications recommended as first-line treatments for neuropathic pain included certain antidepressants (i.e., tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine), calcium channel alpha(2)-delta ligands (i.e., gabapentin and pregabalin), and topical lidocaine. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in selected clinical circumstances. Other medications that generally would be used as third-line treatments include certain other antidepressant and antiepileptic medications, topical capsaicin, mexiletine, and N-methyl-d-aspartate receptor antagonists. Two other national and international associations recently published pharmacologic treatment guidelines for neuropathic pain, which are summarized and contrasted with the NeuPSIG recommendations. Recent guidelines for the use of neurostimulation for the treatment of neuropathic pain also are summarized. For all treatments for neuropathic pain, long-term studies, head-to-head comparisons, and studies of treatment combinations are a priority for future research.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2009.04.007

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

Sorted by citations

Items 601–700 of 785

Related

See all

Metadata

Authors
O'Connor, A. B., & Dworkin, R. H.
Affiliations
University of Rochester Medicine (US)
Corresponding author
O'Connor, Alec B.
ORCID
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
2009-10
Volume
122
Issue
10
Pages
S22-S32
ISSN
0002-9343 (ISSN-L)
DOI
10.1016/j.amjmed.2009.04.007
OpenAlex
W2092918915
Cited by
781
References
36
Citations by year
2026: 9 · 2025: 19 · 2024: 16 · 2023: 21 · 2022: 29 · 2021: 29 · 2020: 23 · 2019: 38 · 2018: 33 · 2017: 50 · 2016: 73 · 2015: 77 · 2014: 73 · 2013: 91 · 2012: 67
FWCI
7.23
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
neuropathic pain, pharmacotherapy, treatment guidelines, antidepressants, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentin, pregabalin, topical lidocaine, opioid analgesics, tramadol, antiepileptic drugs, topical capsaicin, mexiletine, NMDA receptor antagonists, neuromodulation, evidence-based medicine
MeSH terms
Pregabalin, Gabapentin, Amines, Analgesics, Analgesics, Opioid, Anesthetics, Local, Antidepressive Agents, Canada, Cyclohexanecarboxylic Acids, Europe, gamma-Aminobutyric Acid, Humans, International Cooperation, Lidocaine, Neuralgia, Societies, Medical, Tramadol, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review